

1
2 **TNF α SIGNALLING IN THE CUTANEOUS IMMUNE NETWORK**
3 **INSTRUCTS LOCAL Th17 ALLERGEN-SPECIFIC INFLAMMATORY**
4 **RESPONSES IN ATOPIC DERMATITIS**

5
6 **Authors:** Sofia Sirvent^{1#}, Andres Vallejo^{1#}, Emma Corden², Ying Teo^{2,3}, James
7 Davies^{1,4}, Kalum Clayton¹, Eleanor Seaby⁵, Chester Lai³, Sarah Ennis⁵, Rfeef Alyami³,
8 Lareb Dean⁶, Matthew Loxham⁶, Sarah Horswill², Eugene Healy^{2,3}, Graham Roberts^{2,5},
9 Nigel J. Hall^{2,5}, Clare L. Bennett⁴, Peter Friedmann³, Harinder Singh⁷, Michael Arden-
10 Jones^{2,3,8}, Marta E Polak^{1,8*}

- 11
12 1. Systems Immunology Group, Clinical and Experimental Sciences, Faculty of
13 Medicine, University of Southampton; Southampton, UK
14 2. University Hospital Southampton NHS Foundation Trust, Southampton, UK
15 3. Dermatopharmacology, Clinical and Experimental Sciences, Faculty of Medicine,
16 University of Southampton; Southampton, UK
17 4. Department of Haematology, University College London (UCL) Cancer Institute;
18 London WC1E 6DD, UK
19 5. Human Development and Health, Faculty of Medicine, University of
20 Southampton; Southampton, UK
21 6. BRC, Clinical and Experimental Sciences, Faculty of Medicine, University of
22 Southampton; Southampton, UK
23 7. Center for Systems Immunology, Departments of Immunology and
24 Computational and Systems Biology, The University of Pittsburgh; Pittsburgh,
25 USA
26 8. Institute for Life Sciences, University of Southampton; Southampton, UK

27 # These authors contributed equally

28
29 *Correspondence to
30 MEP: m.e.polak@soton.ac.uk
31 Dr. Marta E Polak
32 Systems Immunology Group
33 Clinical and Experimental Sciences
34 Faculty of Medicine
35 University of Southampton,
36 SO16 6YD, Southampton, UK

41 **Abstract:**

42 Accurate regulation of cutaneous immunity is fundamental for human health and quality
43 of life but is severely compromised in inflammatory skin disease. To investigate the
44 molecular crosstalk underpinning tolerance vs inflammation in human skin, we set up a
45 human in vivo allergen challenge study, exposing patients with atopic dermatitis (AD) to
46 house dust mite (HDM). Analyses of transcriptional programmes at the population and
47 single cell levels in parallel with immunophenotyping of resident and infiltrating immune
48 cells indicated that inflammatory responses to HDM were associated with immune
49 activation in Langerhans cells (LCs) and cutaneous T cells. High basal level of TNF α
50 production by cutaneous Th17 T cells predisposed to an inflammatory reaction and
51 resulted in formation of hub structures where LCs and T cells interacted, leading to loss
52 of functional programming in LCs. Additionally, single nucleotide polymorphisms in MT1X
53 gene associated with enhanced expression of metallothioneins and transcriptional
54 programmes encoding antioxidant defences across skin cell types in non-reactive
55 patients, were protective against T cell mediated inflammation. Our results provide a
56 unique insight into the dynamics of immune regulation in the human skin and define
57 regulatory circuits that can be harnessed to improve skin health and treat disease.

58

59

60 Main Text:

61 INTRODUCTION

62 Body surfaces such as the skin, which form the interface with the environment, play
63 a vital role in sensing whether environmental insults are “dangers” and communicate this
64 to the adaptive immune system¹⁻⁵. Healthy skin is able to maintain immune homeostasis
65 despite of constant environmental insults and an inhabiting biofilm of microbiota.
66 However, in chronic inflammatory skin conditions such as atopic dermatitis (AD), this
67 immunotolerance is breached resulting in uncontrolled immune responses to otherwise
68 innocuous allergens, resulting in flares and exacerbations⁶⁻⁸.

69
70 AD is one of the most prevalent inflammatory skin conditions, affecting up to 20% of
71 children and 4-7% of adults in European countries^{9,10}. 20-30% of AD cases are refractory
72 to treatment, and hence very difficult to manage¹¹. Importantly, even though attributing
73 definite causes for eczematous reactions is often impossible, environmental allergens
74 such as pollens, dust mites, pet dander from cats and dogs, moulds and human dandruff,
75 are the commonest triggers inducing allergic immune responses in eczema^{8,12}. Such
76 aberrant allergic responses are thought to be a result of a complex crosstalk between an
77 environmental trigger, impaired skin barrier and Th2 adaptive immune activation, resulting
78 in chronic, prolonged inflammation, and uncontrolled flares^{1,13-15}. Interestingly, even
79 though Th2, the key immunophenotype characterising the skin of patients with AD, is
80 overexpressed in the lesional skin, it is also present in the clinically non-inflamed sites
81^{16,17}, putting in question its definitive role as a sole driver for flares and acute responses.

82
83 Advances applying next generation sequencing technologies at the single-cell level
84 resolution progressed our understanding of the complexity of multicellular interactions
85 driving skin disease pathology. Recent research indicates that the regulatory function is
86 dispersed across multiple cell types, cooperating in homeostasis, including immune cells
87 (dendritic cells, T lymphocytes) and parenchyma (keratinocytes, neurons)¹⁸⁻²⁰. While
88 several studies identify that intricate crosstalk between the parenchyma and immune cells
89 is critical for skin homeostasis², the exact nature of the crosstalk regulating induction of
90 inflammation versus protecting the tolerance and immune homeostasis has not been
91 elucidated.

92
93 We sought to delineate the specific interactions within the multicellular cutaneous
94 network underpinning development of cutaneous T-cell mediated immune responses to
95 allergen in skin of patients with AD. A long-standing clinical observation indicates that
96 only a proportion of patients with detectable allergic responses on blood test have positive
97 eczematous responses to local skin challenge with the same allergens. While patients
98 with severe AD show a significantly higher frequency of IgE reactivity to allergens such
99 as cat (Fel d 1) and house dust mite (HDM, Der p 1, 4 and 10)²¹, it is not understood
100 what determines whether such skin reactivity is present, or why, in some patients with
101 positive blood-derived T cell reactivity to allergens, a skin challenge fails to elicit an
102 eczematous response.

103
104 To address this question, we set up a human *in vivo* challenge model exposing
105 patients with AD to a common aeroallergen, house duct mite (HDM), and investigated
106 transcriptional programmes and function of resident and infiltrating immune cells in

107 reactive versus non-reactive patch test sites. This unique approach allowed us not only
108 to delineate a network of interactions in human skin changing dynamically upon exposure
109 to allergen but progressed our understanding of molecular mechanisms safeguarding
110 cutaneous homeostasis. Our analysis indicates that responses to HDM are mediated by
111 Th17 TNF-expressing T cells in reactive patients, driving rapid expansion and
112 overactivation of Langerhans cells (LCs). Interestingly, protection against T cell-mediated
113 inflammation is likely to be conferred by an elaborate network of interactions, including
114 antioxidant responses in the parenchyma. This network contributes to cutaneous non-
115 reactive state, preventing T cell activation and LC exhaustion. It is therefore likely, that
116 therapeutic interventions aimed towards disrupting Th17/TNF α mediated immune cross
117 talk, or directed towards enhancing antioxidant responses, can be harnessed to improve
118 skin health and prevent exacerbations of atopic dermatitis.

119

120 RESULTS

121


122 ***In vivo* allergen challenge model to investigate mechanisms of local immune** 123 **responses in human skin.**

124

125 To investigate the behaviour of systemic and cutaneous human immune systems upon
126 exposure to an allergen, we set up a human *in vivo* allergen challenge study (Figure 1A).
127 We recruited 28 adult patients with moderate to severe atopic dermatitis under the care
128 of a dermatologist in a tertiary referral center. Skin barrier integrity, systemic blood
129 responses and responsiveness to allergen in skin prick test (SPT) were used to assess
130 structural and systemic parameters. The study group comprised 15 males, 13 females,
131 89% (25/28) of Caucasian ethnicity, with median age = 37 years, (IQR 24.25-53.50),
132 (Supplementary Figure 1A, Supplementary Table 1). Eczema severity scores (EASI)
133 indicated moderate to severe disease (median = 17.7, IQR:10.2 – 30.9, max = 51.4,
134 Supplementary Figure 1A, Supplementary Table 1). Skin barrier was measured as
135 transepidermal water loss (TEWL) of non-eczematous sites and was impaired in the AD
136 patients: median = 17.7 g/m²h, IQR:13.3 – 30.7, max = 85.0 compared to healthy; median
137 = 8.1 g/m²h, IQR = 5.9-10.8, p<0.0001, Supplementary figure 1B). Systemic immune
138 response to HDM was assessed using skin prick test (SPT). 27/28 (96%) patients showed
139 positive SPT reactions to a range of allergens, and the reaction to HDM was one of the
140 strongest (median wheal area 19mm², IQR: 13-26 mm², Supplementary Figure 1C,
141 Supplementary Table 1). All patients had atopic dermatitis (diagnosed by dermatologist
142 as per UK Working Party diagnostic criteria²²), and the majority suffered with hay fever
143 (24/28, 86%) and asthma (21/28, 75%) (ISAAC questionnaire, Supplementary Figure 1D).
144 Local T cell mediated responses to HDM were measured via *in vivo* allergen exposure
145 patch test and assessed by the clinician. 48 hours post application of a patch test to
146 buttock skin, 11 out of the 28 patients showed clear positive reactions to HDM, and hence,
147 were denoted as “HDM-reactive”. In 12 patients, HDM did not induce a visible response,
148 thus they were labelled as “HDM-non-reactive” (Figure 1B). Four patients reacted to the
149 control patch and were thus labelled as “irritated control reactions”, while 1 patient
150 developed redness in the patch test site which was classified by the clinician as not
151 related to the patch test. This patient was excluded from group analysis.

152

153 To delineate the cellular and molecular determinants underpinning local cutaneous HDM
154 reactivity versus local tolerance, 6mm punch biopsies were taken from control and HDM
155 patch test sites 48h post *in vivo* challenge with the allergen, representing the baseline
156 and allergen exposed state of skin. To delineate key cell populations, and molecular cross
157 talk pivotal for the T cell-mediated responses developing *in vivo* in human skin we
158 leveraged systems immunology approaches for analysis of next generation
159 transcriptomic and genomic data.
160



161
162
163 **Figure 1. *In vivo* allergen challenge model to investigate mechanisms of local immune responses**
164 **in human skin.**
165 A) Human *in vivo* allergen challenge set-up. 6mm biopsies taken 48h after application of control (baseline)
166 and HDM (challenge) patch are processed to investigate transcriptional networks and regulatory
167 interactions underpinning T cell mediated responses to allergen (B) Representative images of non-reactive,
168 irritant, and reactive patch test responses to control (left) and HDM (right) allergen, 48 post patch
169 application. Numbers of patients in each group given. TEWL: trans epidermal water loss, SPT: Skin Prick
170 Test, FLG: Filaggrin status
171

172 **Reactivity to HDM is mediated by co-expansion of T cells and LCs.**
173

174 One of the possible explanations for the observed lack of responses to HDM in non-
175 reactive patients with known T cell reactivity is a difference in the epidermal permeability
176 barrier, providing better protection against antigen penetration in those patients. However,
177 in our cohort of patients, the measured TEWL level indicated greater epidermal
178 permeability in non-reactive patients ($p=0.044$, Mann-Whitney test, Figure 2A)
179 Interestingly, high TEWL seemed to predispose to irritated control responses, perhaps

180 highlighting that severely impaired skin barrier facilitates irritant inflammatory reactions.
181 Furthermore, PCR analysis of patient PBMCs showed that the prevalence of mutations
182 in filaggrin (FLG) gene, including 2282del4, R501X, S3247X, R2447X (Fig 2B), was
183 comparable between HDM-reactive and non-reactive patients ($p > 0.9$, χ^2 test).
184 Subsequently, seven loss of function variants were identified in FLG from whole exome
185 sequencing, validating and extending the PCR results. The additional three variants
186 (Gly1109GlufsTer13, Ser2817AlafsTer75 and Gly323X) were of high quality, had an allele
187 balance > 0.19 , and did not indicate differences between HDM-reactive and non-reactive
188 patients ($p = 0.44$, χ^2 test, Supplementary Figure 2A, Supplementary Table 2). The
189 integrity of transcriptional programming relation to the epidermal barrier from reactive and
190 non-reactive patients was further confirmed using single cell transcriptomic data,
191 indicating programmes encoding tight junctions, desquamation, keratinization,
192 cornification, lipid metabolism and desmosomes were not compromised in the skin of
193 reactive patients (Supplementary Figure 2B, $n=6$ paired biopsies, Supplementary Table
194 3).


195
196 In contrast to lack of differences in skin barrier function, the wheal areas of HDM-positive
197 SPT were significantly greater in patients with HDM-reactive patch tests (Figure 2C, left
198 panel, $p = 0.022$, t-test), in agreement with observations by others²³. Interestingly,
199 cutaneous CD3+ T cell infiltration at baseline was higher in those patients, possibly
200 indicating a higher immune activation status in skin (Figure 2D, right panel, $p = 0.046$, t-
201 test). We therefore sought to delineate the immune mechanisms underpinning and
202 coordinating local cutaneous responses to an allergen.

203
204 Following HDM application, there was no significant expansion of T cells in non-reactive
205 patch tests or in irritated control reactions (Figure 2E,G), in comparison to the control
206 patch tests. In contrast, in reactive patients, the higher frequency of T lymphocytes at the
207 baseline translated into higher expansion post patch test ($p=0.0001$, Figure 2F,G). The
208 proportion of HLADR+ cells was visibly higher in responding patients, therefore we sought
209 to determine which population of local antigen presenting cells could be sustaining T cell
210 activation. Quantification of the proportions of LCs (CD207+ CD1a+) versus dermal DC
211 (CD207-CD1a^{dim}) in skin biopsies before and after patch testing (Figures 2H,I,
212 Supplementary Figure 2C) confirmed that a relative expansion of LCs and dermal DCs in
213 reactive, but not tolerant skin compared to baseline.

214
215 We observed, a strong correlation between the increase in fold change of LCs and T cells
216 compared to baseline ($r^2=0.59$, $p < 0.0001$, Figure 2L) suggesting that immune crosstalk
217 between these cells perpetuates the responses to allergen. In comparison, correlation
218 between dermal DC and T cells was much weaker (Supplementary Figure 2D). In-situ co-
219 localisation of LC (green) and T cells (red) was confirmed in patients reacting to HDM
220 (Figure 2L). Intriguingly, they created hubs akin to tertiary immune structures, inducible
221 skin-associated lymphoid tissue (iSALT) previously described in a mouse model of
222 contact dermatitis^{24,25}. While these structures were less frequent in the control skin of
223 reactive patients, T cells were localised in closer proximity to the epidermis, compared
224 with that of non-reactive patients (Supplementary Figure 2E).

225

226
227



228
229

Figure 2. Reactivity to HDM is mediated by co-expansion of T cells and LCs.

230 A) Functional assessment of skin barrier: TEWL measurements across patient groups B) Number of irritant
231 (IRR), non-reactive (NON), and reactive (REAC) cases with loss of function (LoF) variants in FLG compared
232 to wildtype (WT). C) Skin prick test responses to HDM across patient groups, wheal area mm², D)
233 Percentage of CD3+ T cells in control patch test sites identified by flow cytometry. Statistical significance
234 assessed by t-test E-I) Frequency of immune cells in control and HDM patch tests from non-reactive vs
235 reactive patients, measured by flow cytometry. Number in the graph indicates percentage of cells in the
236 positive gate. Representative examples. E-G) CD3+ T lymphocytes, H-J) CD207/CD1a positive LCs. G,I)
237 Fold changes (FC) in percentage of detected immune cells between HDM patch test and control patch test
238 from patients with irritant, non-reactive and reactive reactions to HDM. Statistical significance assessed by
239 t-test J) Correlations between fold changes in percentage of CD3+ T cells and LCs. Pearson correlation
240

241 coefficient shown. K) Immunofluorescence staining of HDM-reactive patch test site. Inserts show the
242 indicated optical fields at the epidermis (top) and in the dermis (bottom). Hub structures of co-localising
243 CD207 (green) and CD3 (red) in dermis. Epidermal layer stained with multi-cytokeratin (blue). DAPI stain
244 for nuclei (grey).

245


246 **HDM reactivity in reactive patients is mediated by LC : T cell TNF crosstalk and** 247 **impairs LC transcriptional programming**

248

249 The proximity of localisation and co-expansion of LCs and T cells in reactive patch tests
250 suggests that immune crosstalk between these cells is important for T cell mediated
251 cutaneous reaction to HDM. To investigate in depth transcriptional changes in LCs in non-
252 reactive vs reactive patients, CD207+CD1a+ LCs were purified from control and HDM-
253 challenged patch test sites, by fluorescence activated cell sorting (Supplementary Figure
254 3A), and RNA isolated for whole transcriptome analysis using RNA sequencing.
255 Transcriptome profiles from LCs in control biopsies across patient groups were consistent
256 with steady-state LCs described by us recently²⁶ with programmes encoding cell cycle,
257 including oxidative phosphorylation (BH adj p < 2x10E-8), antigen processing and
258 presentation (BH adj p < 2x10E-8), protein targeting to ER (BH adj p < 2x10E-36) and
259 protein catabolic process (BH adj p = 2x10E-25), (Figure 3A, Supplementary Table 4).
260 Transcript-to-transcript correlation analysis of 28032 filtered and normalised transcripts
261 (BioLayout r=0.85, MCL = 1.7, minimal cluster size = 10 genes) identified 10 clusters of
262 1115 co-expressed genes, clearly split into two distinct structures (Supplementary Figure
263 3B). Surprisingly, despite the significant expansion of LC numbers in the reactive HDM-
264 patch test sites, our analyses uncovered impairment of LC transcriptional programming
265 in those samples in comparison to both paired control patch test and to non-reactive
266 patches. The majority of genes (691, Clusters 01,03,04,05,07,08,10) followed a
267 characteristic pattern of expression, with significant downregulation after exposure to
268 HDM in cells isolated from reactive patients (Figure 3B, Supplementary Figure 3C,
269 Supplementary Table 5). This was reflected in downregulation of LCs core transcriptomic
270 programmes, such as protein targeting to ER (BH adj p = 5.67E-82), ubiquitin proteinase
271 ligase binding (BH adj p = 5.83E-10), and antigen processing and presentation (BH adj p
272 =7.38E-9), described by us as key for LC function²⁶. Flow cytometric analyses of LCs
273 across non-reactive and reactive patch-tests indicated that in non-reactive and irritant
274 responses, exposure to HDM increased expression of CD207, the LC hallmark antigen
275 uptake receptor. In contrast, levels of CD207 were markedly decreased in reactive
276 patches, indicating reduction in LCs antigen acquisition and processing function,
277 consistent with observed transcriptional changes (Figure 3D). Unbiased weighted gene
278 expression network analysis (WGCNA,²⁷) investigating dependencies between bulk LC
279 transcriptomes and clinical parameters (including TEWL measurements, SPT response,
280 EASI scores), and skin immune parameters (CD3+ T cell infiltration, activation of Th
281 subtypes in blood as measured by flow cytometry) identified 7 modules of co-expressed
282 genes. This unbiased analysis confirmed strong correlation existed between changes of
283 LCs transcriptome modules, disease severity as measured by EASI (module yellow,
284 r=0.48, adj p = 0.001), and level of CD3+ T cell infiltrate in the skin (module turquoise,
285 (|r|=0.31, adj p = 0.04, Supplementary Figure 3D, Supplementary Table 6).

286 To identify the molecular interactions underpinning LC activation and apparent loss of
287 functional transcriptome, we assessed transcriptional programmes and molecular cross

288 talk in further 6 biopsies from 1 non-reactive and 2 reactive patients using single cell RNA-
 289 sequencing. Ligand-receptor analyses of single cell transcriptomes isolated from full skin
 290 biopsies confirmed that a signalling edge from activated T lymphocytes delivered
 291 activation stimulus via TNF: TNFRSF1B uniquely in HDM-reactive patients (Figure 3E-
 292 G). This edge was present at baseline, and became dominant after exposure to HDM
 293 (Figure 3E). In contrast, in non-reactive patients, a network of epidermal signalling to LCs
 294 was provided by an active crosstalk with multiple cell types, including structural and
 295 immune cells.
 296 Interestingly, the same set of genes was differentially expressed at baseline between non-
 297 reactive and reactive patients (Figure 3B, $p < 0.0001$), indicating that LCs in reactive
 298 patients were more highly activated before exposure to allergen, and pointing to TNF α as
 299 the driving stimulus (Supplementary Table 5).
 300



302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350

Figure 3 HDM reactivity in reactive patients is mediated by LC : T cell TNF crosstalk and impairs LC transcriptional programming

A) Quantitative transcriptional profile of LC at baseline across all patch tests. Average gene expression binned for the expression level shown. Gene ontology ranked with FDR corrected p-values given for each gene expression level bracket. TMM-normalised counts. B) Average log gene expression levels in the main cluster encoding LC core programmes across non-reactive and reactive patients. Transcript to transcript clustering Biolayout, 691 genes, $r=0.85$, $MCL=1.7$. CR: control reactive, HR: HDM reactive, CNR: control non-reactive, HNR: HDM non-reactive C) Gene Ontologies overrepresented in the main cluster encoding LC programmes, TopGene D) HDM-induced change in CD207 expression levels measured by flow cytometry across patient groups $n=27$, t-test E) Crosstalk analysis of interactions overexpressed between cell populations in non-reactive (blue) and reactive (red) patients after stimulation with HDM. F) $TNF\alpha$ expression across T cell clusters (single cell data, fresh full skin biopsy, $n=6$ paired biopsies from 3 patients, Drop-seq) G) Dotplot of TNF interactions detected between mature (mLC) and steady state LC (ssLC) and different T cell populations. The size of the dot indicates $-\log(10)$ pvalue, the color denotes $\log(2)$ average activation strength.

Activated TNF-expressing Th17 cells are significantly enriched at baseline in reactive patients

Given the observed importance of TNF signalling for HDM responses, we next sought to delineate the specific source population and further delineate the crosstalk programming cutaneous responses to HDM. To reliably track rare populations including specific T cell types, and transcriptional programmes at the level of transcription factors within dissociated skin biopsies we applied Constellation-seq²⁸, a highly sensitive transcriptome read-out (Supplementary Table 7). Constellation-seq analysis identified 6 distinct T cell populations, annotated as CD4 naïve T cell, CD4 follicular helper T cells (Tfh), CD8 cytotoxic T cells, primed T cells, regulatory T cells (Tregs), and a small cluster of $\square\square$ T cells, using Human Cell Atlas signatures²⁹ (Figure 4A,B).

Comparative analyses of the prevalence and activation of specific T cell clusters across patient groups showed that T cell changes in response to allergen were quantitative rather than qualitative (Figure 4C), as cell numbers at baseline differed significantly between reactive and non-reactive patients (Figure 4D). Together with changes in T cell numbers observed by flow cytometry (Figure 2G), this strongly indicated that the inflammatory process in HDM patch test site is driven by T cell expansion from populations present at baseline. Interestingly, a trend was observed for HDM-induced expansion of Tregs in patients clinically non-responding to HDM (Supplementary Figure 3A). Contrasting T cell populations in reactive and non-reactive patients indicated that in reactive patients higher activation status of T cells was seen across clusters, manifested by up-regulation of *NFATC2*, *JUN* and NFkB transcription factors (as exemplified by *RELB*, Figure 3E). In contrast, T cells from non-reactive patients expressed transcription factors regulating tolerogenic properties (*STAT5B*) (Figure 3E). Consistently, genes up-regulated in reactive patients encoded T cell activation via JAK-STAT and Wnt signalling pathways (Figure 3F). In contrast, in patients non-reactive to HDM, T cells showed enrichment of processes of cellular senescence (Figure 3G).


Unbiased clustering analysis revealed statistically significant overrepresentation of TNF expressing T cells within Tfh cluster (Figure 4A,K, TWEAK signaling pathway enriched in

351 CR vs CNR, adj p value 0.019) in unstimulated skin of patients reactive to HDM. Testing
352 for specific T cell transcriptional programmes including Th1, Th2, Th17, Th22, and Treg
353 (as defined by HCA), confirmed enrichment in Th17 cells, overrepresented across Tfh
354 and CD4 naïve clusters, co-localising with TNF-expressing T cells. These cells were
355 highly activated at baseline, delineating a specific immunophenotype of
356 CD3+IL17+TNF+CD69+ T cells overrepresented at baseline in the skin of patients
357 reactive to HDM.

358
359 In contrast, Th1, Th2 and Th22 immunophenotypes were shared between cells across
360 patient groups and T cell populations, resembling continuous phenotype clouds of T cells
361 in gut tissue, as described by Kiner and colleagues³⁰. Interestingly, even though Th2
362 determinants were expressed more strongly in patients with reactive HDM-patch tests,
363 Th2 polarisation, albeit weaker, was also evident in non-reactive patients, both at baseline
364 and following *in vivo* challenge with the allergen (Supplementary Figure 4B,C), in
365 agreement with earlier findings reporting Th2 responses in non-lesional eczema skin^{16,17}.

366
367 To test, whether the Th17 overexpression was translated into functional protein synthesis,
368 we assayed cytokine expression in peripheral blood mononuclear cells from reactive and
369 non-reactive patients. While no differences were discovered in IL13-producing CD4+ T
370 cells between patient groups (Supplementary Figure 4C), IL-17 producing T cells were
371 significantly overrepresented in blood of reactive patients even prior to stimulation with
372 HDM (Figure 4J). The importance of TNF for inter-cellular communication in the skin of
373 reactive patients was next confirmed in crosstalk analyses, demonstrating a TNF:
374 TNFSFRB signaling edge between T cells and APCs, already present at baseline, and
375 strengthened on exposure to HDM in reactive patients.

376



377
378
379 **Figure 4 Activated TNF-expressing Th17 cells are significantly enriched at baseline in reactive**
380 **patients**

381 Constellation-seq analysis enriched for 1161 transcripts in 2374 single T lymphocyte cells from patch test
382 skin biopsies, n=10 patients, 5 per group A) UMAP plot depicting clustering of T lymphocyte populations B)
383 Cell subset defining markers (Wilcoxon rank test). C) T cell subset composition across patient groups D)
384 Number of T cell transcriptomes in control non-reactive (CNR) and reactive (CR) patients E) Top
385 transcription factors expressed in T cells from reactive (CR) and non-reactive (CNR) patients at baseline

386 F,G) Top biological pathways enriched at baseline in DEGs from (F) patient reactive (CR) and (G) non-
387 reactive (CNR) to HDM (KEGG database) H) UMAP plots showing expression of Th17 gene signature I)
388 Th17 gene signature across patient groups, dotplot: size depict % of expressing cells, colour intensity
389 encodes mean expression in group. J) %IL17 producing CD3+CD4+ Tcells from PBMCs in non-reactive
390 (CNR) and reactive (R) patients. T-test. K) UMAP plots showing expression of *TNF* and *TNFRSF1B* across
391 T cell (left) and APCs (right) L) *TNF* and *TNFRSF1B* expression level across patient groups, dotplot: size
392 depict % of expressing cells, colour intensity encodes mean expression in group. CR: control reactive, HR:
393 HDM reactive, CNR: control non-reactive, HNR: HDM non-reactive
394

395 **Sub-clinical inflammation and environmental stress in differentiated** 396 **keratinocytes poise immune status of reactive patients**


397
398 Next, we sought to delineate the cellular and molecular drivers of activated T cell status
399 in the skin. Scanpy analysis³¹ of Constellation-seq data of 25844 cells filtered for number
400 of expressed genes and viability as assessed by mitochondrial gene content
401 (Supplementary Figure 5A), identified 15 major cell clusters, representing cell populations
402 found in skin biopsies (Leiden algorithm, $r=0.5$, Figure 5A, Supplementary Table 8). Cell
403 identity was confirmed using HCA marker genes²⁹ (Figure 5B). Distinct clusters grouped
404 keratinocytes (undifferentiated and differentiated), immune cells (including APCs and T
405 cells), four populations of fibroblasts (F1-F4), vascular endothelial cells, lymphatic
406 endothelial cells and pericytes and melanocytes (Supplementary Table 8).
407

408 Differential gene expression analyses performed for each specific cell population between
409 sample phenotypes indicated that amongst all the cell populations the most DEGs
410 differentiating reactive and non-reactive patients were expressed at baseline by
411 differentiated KCs (825 DEGs, MAST, FDR<0.05, Supplementary table 8). These
412 encoded skin differentiation (FDR $p=6 \times 10^{-13}$), hyperkeratosis (FDR $p=4 \times 10^{-3}$) and
413 skin inflammation (FDR $p=3 \times 10^{-3}$ (ToppGene, Supplementary table 9). Testing for
414 enrichment of pre-defined signatures confirmed that in reactive patients, there was
415 enhanced inflammatory status of differentiated keratinocytes at baseline (Figure 5C,D),
416 which was validated by unbiased single cell whole transcriptome analysis and could be
417 localised to the spinous layer (Supplementary Figure 5 D,E). The activated immune status
418 was epitomised by kinase activity (Supplementary table 9). Interestingly, one of the most
419 highly overexpressed genes, *MAP4K5*, has been implicated in responses to
420 environmental stress (Figure 5E).
421

422 Even though very few differentially expressed genes were found in other cell populations
423 at baseline, analysis of molecular crosstalk indicated their importance in signalling to T
424 lymphocytes. A signalling edge between *FAM3C* on mast cells to *CLEC2D* was
425 associated with driving T cell maturation and activation to terminal differentiation,
426 demonstrated by *KLRB1* expression (Figure 5G,H). Importantly, activation via *CLEC2D*
427 has been shown to drive *TNF* expression in multiple cell types³² providing a plausible
428 explanation for *TNF*-expressing Tfh T lymphocytes observed at baseline in HDM-reactive
429 patients.

430 While differences at baseline localised specifically to epidermis, in reactive patients
431 exposure to HDM induced activation across many more skin cell types, including
432 fibroblasts and venous endothelial cells, which corresponded to the inflamed, lesion
433 status of the patch test (Supplementary Figure 5, Supplementary Table 10). Importantly,

434 after the exposure to HDM, differentiated keratinocytes initiated HIF1 signalling pathway,
 435 providing further evidence that the cutaneous inflammation was associated with hypoxia
 436 and oxidative stress (Supplementary Figure 5).
 437



439 **Figure 5 Sub-clinical inflammation drives responses to allergen**

440 Constellation-seq analysis enriched for 1161 transcripts in 25844 single cells from patch test skin biopsies,
441 n=10 patients A) UMAP plot depicting clustering of specific cell populations B) Cell subset defining markers
442 (Wilcoxon rank test). C,D) Expression of inflammation signatures in differentiated keratinocytes. E)
443 Expression of MAP4K5 in differentiated keratinocytes across patient groups. F) Top pathways
444 overrepresented at baseline in differentiated keratinocytes from reactive patients. G) Sankey plot listing all
445 interactions associated with FAM3C and CLEC2D. H) Dotplot demonstrating changes in the expression
446 levels on source and receiving cells among the experimental groups. dotplot: size depict % of expressing
447 cells, colour intensity encodes mean expression in group. CR: control reactive, HR: HDM reactive, CNR:
448 control non-reactive, HNR: HDM non-reactive

449

450 **Enhanced expression of metallothionein genes protects non-reactive patients**
451 **from HDM-induced T cell-mediated inflammation**

452


453 Having identified that baseline epidermal sub-clinical inflammation, high activation status
454 of the cutaneous immune compartment, and TNF signalling predisposed to positive
455 inflammatory responses to HDM, we sought to evaluate the parameters protective against
456 inflammation and conducive to local immunotolerance. While analyses of differentially
457 expressed genes across different skin populations identified only sporadic genes up-
458 regulated in non-reactive patients, these differentially up-regulated genes consistently
459 included members of metallothionein family, with *MT2A* being the top overexpressed
460 gene in non-reactive fibroblasts and venous endothelium (FDR $p = 0.015$, supplementary
461 Figure 6A). Drop-seq analyses of freshly dissociated biopsies (n=6) confirmed the high
462 expression of metallothionein gene family across cell populations in the non-reactive vs
463 reactive patients (Figure 6A,B). To ensure that the detection limits and drop-outs were
464 not masking metallothionein expression we further corroborated the results using high-
465 sensitivity Constellation-seq (Figure 6C). While expression of metallothionein transcripts
466 was reduced on exposure to HDM in all patients, cells from biopsies non-reactive to HDM
467 retained some expression of metallothioneins (Figure 6C).

468 Metallothioneins (MT) are small, cysteine-rich heavy metal-binding proteins which
469 participate in an array of protective stress responses. Given the uniform downregulation
470 across the skin cell types, we sought to test whether DNA polymorphisms could underpin
471 differences in non-reactive vs reactive patients. Hypothesis driven GenePy logistic
472 regression analysis³³ of 34 genes encoding oxidative stress responses, and key
473 immunological and structural features predefined in the study (Supplementary Table 11),
474 identified *MT1X* as the top gene differentiating patient groups. A chi-square test of
475 independence was performed to examine the relation between single nucleotide
476 polymorphism (SNP) in *MT1X* and reactivity to HDM. The relation between these
477 variables was close to significant, $\chi^2 = 3.96$, $p = 0.076$, indicating that existence of a
478 SNP in *MT1X* protected from allergen-driven inflammation (Figure 6D). Examining the
479 genomic region of *MT1X*, we confirmed, that both SNPs (16:56682411:G>T and
480 16:56682435:C>A) were localized in the promoter and enhancer region of *MT1X* gene
481 (Supplementary Figure 6B).

482

483 Interestingly, even though alterations in *MT1X* promoter sequence appeared to underpin
484 reactivity to HDM, all reactive patients degraded mRNA for all type 1 metallothioneins on
485 exposure to the allergen. Functional human metallothionein genes are clustered on
486 human chromosome 16, and they respond to environmental stresses in a coordinated

487 manner³⁴. This posed a possibility of existence of additional inducible regulation of
488 metallothionein expression. WGCNA analysis pointed to a specific module of genes
489 (turquoise, Supplementary Figure 3D, Supplementary Table 6), the expression of which
490 varied with the level of CD3 infiltrate. Genes correlating positively with CD3 infiltrate
491 encoded signalling receptor activity. In contrast, genes whose expression decreased with
492 CD3+ T cell frequency encoded cellular homeostasis including response to metal ions
493 and to cytokine stimulus (Supplementary Figure 6C, Supplementary Table 12),
494 comprising several members of metallothionein family (*MT2A*, *MT1G*, *MT1X*). Strikingly,
495 LCs from samples where CD3 T cells expanded on exposure to HDM (red) were
496 separated by reduced expression of genes in the turquoise module, including
497 metallothioneins *MT2A*, *MT1G*, *MT1X*, ferritin chains (*FLT*, *FTH1*) and heme oxygenase
498 (*HMOX1*) (Figure 6E), creating a network of antioxidant defences (Figure 6F). We next
499 confirmed the expression of metallothionein genes was decreased in chronic AD lesions
500 (Figure 6G) and compromised across a range of T-cell mediated skin diseases, in
501 comparison to healthy skin (Figure 6H). Furthermore, analysis of publicly available data
502 of keratinocytes exposed to a range of cytokines, indicate, that expression of
503 metallothioneins can be downregulated by IL17a and TNF α (Figure 6I), providing an
504 inducible mechanism by which T cell mediated allergic immune responses deplete the
505 RedOx buffer, and render the skin susceptible to chronic inflammation.
506



507
508 **Figure 6 Enhanced expression of metallothionein genes protects non-reactive patients from HDM-**
509 **induced T cell-mediated inflammation**

510 A,B) Violin plots showing expression of metallothioneins across cell types in control patch tests from
511 patients with non-reactive (A) and reactive (B) patch test reactions to HDM. SCRAN-normalised single cell
512 RNA expression shown for each transcript. n=3, fresh skin biopsies, Drop-seq C) Heatmap comparing
513 levels of expression for metallothioneins in whole skin using high sensitivity Constellation-seq method, n=10
514 skin donors. CR: control reactive, HR: HDM reactive, CNR: control non-reactive, HNR: HDM non-reactive
515 D) Distribution of WT vs SNP in MT1X gene across patient groups E) Heatmap showing segregation of
516 patients with CD3 T cells decreasing (blue), expanding (red) and stable (black) in reaction to patch test
517 using fold change expression values of 100 top differentially regulated genes in module turquoise. Genes
518 overexpressed in non-reactive samples contain members of metallothionein family. F) Protein interaction
519 analysis (STRING) depicting metallothionein functional importance for metal transition metal ion

520 homeostasis (red), cytokine mediated signalling (blue) and responses to stress (green) G) Expression of
521 metallothioneins in patients with AD, in lesional (LES) and non-lesional (NLES) skin. H) Expression of
522 signatures encoding metallothioneins (MT), and RedOX, in patients with T-cell mediated skin diseases Z-
523 score, GSE150672 G,H) dotplot: size depict % of expressing cells, colour intensity encodes mean
524 expression in group. Acne: Acne Vulgaris, Alopecia: Alopecia Areata, GA: Granuloma Annulare I)
525 Normalised expression levels of genes encoding *MT1E* and *MT1X* in keratinocytes exposed to IL17a and
526 TNF α . GSE36287.

527

528 **DISCUSSION**

529

530 Accurate regulation of cutaneous immunity is fundamental for human health and quality
531 of life as inappropriate immune activation results in inflammatory disorders, affecting up
532 to 40% of the population^{35–37}. In AD this problem is particularly severe, manifested by
533 frequent exacerbations and resulting in significant morbidity in paediatric and adult
534 patients^{6,8,9}.

535

536 Comparing cutaneous and systemic responses of eczema patients to HDM, we
537 demonstrated that despite evident allergen-specific responses in blood, nearly 50% of
538 patients did not react clinically to an epicutaneous patch test with allergen. We ruled out
539 the possibility that the lack of reactivity might be due to the epidermal permeability barrier
540 preventing penetration of the allergen, as these individuals had a less effective barrier as
541 indicated by increased TEWL. This suggested the existence of local epidermal tolerance
542 in the non-lesional skin and posed a question about the factors regulating the distinctly
543 different outcomes between reactive and non-reactive patients. To explore the molecular
544 and cellular networks underpinning immune reactivity, we took biopsies from control
545 and HDM-exposed sites, and subjected isolated cell populations to micro-bulk and single
546 cell transcriptomic analysis. These were validated with protein expression measured by
547 flow cytometry and *in situ*. We further investigated exome sequence in a subset of genes
548 preselected based on the transcriptomic analysis, to delineate potential single nucleotide
549 polymorphisms which might be conferring protection from allergen-driven skin
550 inflammation. This methodological approach allowed us to contrast immunoreactivity
551 versus tolerance as it is happening in human skin *in vivo*.

552

553 Our study documents that immunotolerance is the baseline state of cutaneous immune
554 network in AD, similar to healthy skin³⁸, and is mediated by numerous interactions across
555 multiple parenchymal and immune cell subsets. In allergen-responsive individuals, this
556 innate state of tolerance is overcome by inflammatory signalling, epitomised in crosstalk
557 between activated Tfh Th17 TNF-expressing T cells and LCs. Importantly, the baseline
558 state in skin is distinctively different in non-reactive and reactive patients. These baseline
559 differences are localised mainly to the epidermis and the immune compartment. In
560 contrast, following allergen application, when the inflammatory reaction has developed
561 and has formed a skin lesion, activation of other cell types becomes evident, similar to
562 changes observed between non-lesional and lesion skin of AD patients^{18,20,29}.
563 Interestingly, our analyses indicate that while sub-clinical inflammation in keratinocytes
564 seems to pre-set the epidermal microenvironment, specific signals from mast cells and
565 fibroblasts, including FAM3C on mast cells to CLEC2D on T cells drive TNF expression.

566

567 The expansion of LC in response to HDM is intriguing; while expansion of dermal DC can
568 be attributed to infiltration of monocytic precursors from blood, the epidermal
569 compartment is independent of blood progenitors. Thus, the expansion would need to be
570 due to local rapid proliferation, differentiation from skin resident precursors or local
571 chemotaxis from epidermis surrounding the patch test site, in response to signals induced
572 in the inflammatory patch test reaction. A similar observation was made recently when
573 contrasting lesional and non-lesional AD skin ²⁹, indicating that allergic reactivity induced
574 by HDM mimics biological changes in chronic lesions, and suggesting LC expansion is
575 an early event in lesion formation. Furthermore, changes we observed in expression of
576 CD207, a key molecule for pathogen sequestration in skin, may point to a mechanism
577 compromising anti-microbial defences in AD skin, and thus perpetuating inflammation.

578
579 The frequency and the state of activation of Tfh Th17 TNF-expressing T cells appears to
580 be critical for subsequent reaction to the allergen. Tfh have been previously implicated in
581 driving re-call allergic responses to HDM in lungs ³⁹. However, our study defines these
582 cells as Th17 TNF-expressing, in contrast to Th2 cells reported by others. Th17 T cells
583 have been already shown to be of importance in AD, expressed at higher levels in skin of
584 children than in adults ¹⁴, and higher in intrinsic AD ¹⁵. Our previous analysis of skin
585 immunophenotypes indicated existence of a specific endotype of Th17 high patients with
586 AD, highly prevalent in chronic lesions ¹⁷. The role of Th17 skin infiltrating T cells in driving
587 acute responses to an allergen could be conceivably executed via contributing to an
588 augmented state of immune readiness, promoting more severe immune reaction. While
589 IL17 has been established as driving innate anti-microbial responses, TNF α is a
590 particularly multifunctional cytokine, exerting effect on numerous skin populations. TNF α
591 drives expression of adhesion molecules in skin of patients with AD, which may facilitate
592 immune cell extravasation ⁴⁰. Together with Th2 cytokines TNF α induces atopic
593 dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids
594 in human skin equivalents ⁴¹. Induced by *S.aureus*, TNF α leads to up-regulation of HLA-
595 DR molecules in keratinocytes and facilitates HDM allergen presentation¹². Inflammatory
596 IL-17 and TNF α secreting CD4(+) T cells have been shown to persist even in highly
597 immunosuppressive cancer environments ⁴², indicating their potential to overcome
598 mechanisms of cutaneous homeostasis.

599
600 TNF α secreted by T cells could play a double role in driving LC function by regulating
601 both LC migration and maturation ^{26,43-46}. Expressed in unperturbed skin, it can drive LC
602 activation. On exposure to HDM, TNF produced by activated T cells will provide a
603 chemotactic signal for LC to migrate out of the epidermis. In the hub structures observed
604 in HDM reactive patients, activated LCs would support T cell activation and survival,
605 perpetuating inflammation. However, in addition to delivering chemotactic and pro-
606 maturation signals, TNF α has cytotoxic functions, likely resulting in the observed
607 expansion and loss of functional transcriptomes of LCs. Several lines of evidence point
608 to the importance of the ability of Langerhans cells (LCs) to induce immunotolerance as
609 critical for cutaneous homeostasis ^{38,47,48}. In this context, loss of LC function could likely
610 lead to uncontrolled inflammation *in situ*, as observed in the HDM reactive patch test.
611 Such exhaustion induced by overactivation has previously been observed in dendritic
612 cells and macrophages in chronic infection and when overwhelmed by antigen load ^{49,50}

613 In contrast to sub-clinical inflammation in the skin of reactive patients, expression of
614 metallothioneins was associated with protection from HDM-driven inflammatory reaction.
615 Levels of expression of metallothioneins seemed to be controlled both at the constitutive
616 (via SNP in *MT1X* gene) and inducible levels (regulated by the acute oxidative
617 stress/inflammation), highlighting the importance of anti-oxidative defences in AD skin.
618 Importantly, anti-oxidative defence was one of the transcriptomic modules critically
619 compromised in LCs from reactive patch test sites. Oxidative stress is one of the key
620 components driving allergic sensitisation, and in asthma models, aeroallergens such as
621 HDM, directly induce production of reactive oxygen species and DNA damage and
622 dampen antioxidant responses^{51,52}. Additionally, we and others demonstrate that
623 cytokine signalling can affect metallothionein expression in an inducible manner. Indeed,
624 increased oxidative stress during AD exacerbation⁵³ and decreased antioxidant capability
625 in children with eczema⁵⁴ has been previously observed. Since oxidative stress itself
626 exhausts antioxidant responses and can be induced by many eczema-associated factors
627 including allergens, hormones and chemicals, it is possible that chronic exposure to such
628 triggers may compromise LC function in the epidermis of individuals with eczema making
629 them less able to maintain cutaneous tolerance and extending our observation beyond
630 the patch test system.

631
632 Based on our analyses, we propose a model in which sub-clinical inflammation exhausts
633 metallothionein stores in the skin of genetically pre-disposed patients. This leads to the
634 poised state of keratinocytes, expressing high levels of *MAP4K5* and other kinases. The
635 sub-cutaneous inflammation is in parallel manifested by infiltration TNF α expressing
636 activated T cells, and activated antigen presenting cells, including LCs. In response to
637 allergen, these quickly initiate inflammatory responses and expand T cell population
638 driving inflammatory reaction. This in turn leads to exhaustion of LCs, uncontrolled
639 inflammation and lesion formation thereby mediating clinical signs of inflammation. In
640 healthy/non inflamed skin allergen exposure, in the absence of subclinical inflammation,
641 mediates immunological non-responsiveness, but in the inflamed skin depleted of
642 oxidative defences, exposure to HDM initiates allergic inflammation.

643
644 Our current study provides a detailed description of cellular and molecular crosstalk in the
645 skin of eczema patients, proposing a mechanism supporting development of allergen-
646 induced inflammation. We conclude, that while immunotolerance conferred by LCs in
647 healthy skin is preserved in non-lesional skin of eczema patients, this tolerance is
648 compromised on activation of allergen-specific T lymphocytes infiltrating skin.
649 lymphocytes infiltrating skin. Therefore, therapeutic strategies aiming to restore the
650 healthier, tolerance-related signaling in the cutaneous immune network could help in
651 preventing eczema exacerbations, harnessed to improving skin health and in relation to
652 treating active skin disease lesions in patients with AD.

653
654
655 **MATERIALS AND METHODS**
656
657 **Study design**

658 Informed, written consent was obtained as per approval South East Coast - Brighton &
659 Sussex Research Ethics Committee in adherence to Helsinki Guidelines (approval:
660 16/LO/0999). Adult AD patients with mild to severe disease (mean objective EASI) were
661 recruited through the Dermatology Centre, Southampton. University Hospital NHS Trust.
662 All AD patients fulfilled the diagnostic criteria for AD as defined by the UK. AD diagnostic
663 criteria²².

664

665 ***In vivo* allergen challenge model**

666 House Dust Mite allergen (ALK-Abello, Horsholm, Denmark AD01-AD10, Citeq Biologics,
667 Netherlands AD11-AD28) has been applied in paraffin via epicutaneous patch application
668 to the upper buttock skin at a non-lesional site (free from eczema) following 10x tape strip
669 procedure to remove stratum corneum, according to our previous method^{1,59}. A control
670 patch was applied in parallel following identical procedure, except for the HDM allergen.
671 In all AD volunteers, this site showed no evidence of active eczema, and the volunteers
672 were not being treated with topical therapy. Clinical responses were quantified 48 hours
673 later at each challenge site by a specialist registrar in dermatology trained in patch testing.
674 6 mm skin biopsies were taken under local anaesthesia from allergen-exposed and
675 control skin.

676

677 For detailed Materials and Methods: Experimental Procedures see Supplementary
678 Materials.

679

680 **References**

681

682 1. Newell, L. *et al.* Sensitization via healthy skin programs Th2 responses in individuals with
683 atopic dermatitis. *J Invest Dermatol* **133**, 2372–2380 (2013).

684 2. Kobayashi, T., Naik, S. & Nagao, K. Choreographing Immunity in the Skin Epithelial
685 Barrier. *Immunity* **50**, 552–565 (2019).

686 3. Cavani, A. *et al.* Patients with allergic contact dermatitis to nickel and nonallergic
687 individuals display different nickel-specific T cell responses. Evidence for the presence of
688 effector CD8⁺ and regulatory CD4⁺ T cells. *J Invest Dermatol* **111**, 621–628 (1998).

689 4. Friedmann, P. S. & Pickard, C. Quantifying human susceptibility to contact sensitization;
690 risk assessments now and in the future. *Contact Dermatitis* **63**, 237–247 (2010).

691 5. Liu, P. T. *et al.* Toll-like receptor triggering of a vitamin D-mediated human antimicrobial
692 response. *Science* **311**, 1770–1773 (2006).

- 693 6. Biedermann, T., Skabytska, Y., Kaesler, S. & Volz, T. Regulation of T Cell Immunity in
694 Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation. *Front*
695 *Immunol* **6**, 353 (2015).
- 696 7. Kapp, A. *et al.* Long-term management of atopic dermatitis in infants with topical
697 pimecrolimus, a nonsteroid anti-inflammatory drug. *J Allergy Clin Immunol* **110**, 277–284
698 (2002).
- 699 8. Werfel, T. *et al.* Exacerbation of atopic dermatitis on grass pollen exposure in an
700 environmental challenge chamber. *J Allergy Clin Immunol* **136**, 96-103.e9 (2015).
- 701 9. Leung, D. Y. M. & Bieber, T. Atopic dermatitis. *Lancet* **361**, 151–160 (2003).
- 702 10. Silverberg, J. I. & Hanifin, J. M. Adult eczema prevalence and associations with asthma and
703 other health and demographic factors: a US population-based study. *J Allergy Clin Immunol*
704 **132**, 1132–1138 (2013).
- 705 11. Arkwright, P. D. *et al.* Management of difficult-to-treat atopic dermatitis. *J Allergy Clin*
706 *Immunol Pract* **1**, 142–151 (2013).
- 707 12. Ardern-Jones, M. R., Black, A. P., Bateman, E. A. & Ogg, G. S. Bacterial superantigen
708 facilitates epithelial presentation of allergen to T helper 2 cells. *Proc Natl Acad Sci U S A*
709 **104**, 5557–5562 (2007).
- 710 13. Brunner, P. M., Guttman-Yassky, E. & Leung, D. Y. M. The immunology of atopic
711 dermatitis and its reversibility with broad-spectrum and targeted therapies. *J Allergy Clin*
712 *Immunol* **139**, S65–S76 (2017).
- 713 14. Esaki, H. *et al.* Early-onset pediatric atopic dermatitis is T(H)2 but also T(H)17 polarized in
714 skin. *J Allergy Clin Immunol* **138**, 1639–1651 (2016).

- 715 15. Suárez-Fariñas, M. *et al.* Intrinsic atopic dermatitis shows similar TH2 and higher TH17
716 immune activation compared with extrinsic atopic dermatitis. *J Allergy Clin Immunol* **132**,
717 361–370 (2013).
- 718 16. Suárez-Fariñas, M. *et al.* Nonlesional atopic dermatitis skin is characterized by broad
719 terminal differentiation defects and variable immune abnormalities. *J Allergy Clin Immunol*
720 **127**, 954-964.e1–4 (2011).
- 721 17. Clayton, K. *et al.* Machine learning applied to atopic dermatitis transcriptome reveals distinct
722 therapy-dependent modification of the keratinocyte immunophenotype. *Br J Dermatol*
723 (2020) doi:10.1111/bjd.19431.
- 724 18. He, H. *et al.* Single-cell transcriptome analysis of human skin identifies novel fibroblast
725 subpopulation and enrichment of immune subsets in atopic dermatitis. *J Allergy Clin*
726 *Immunol* **145**, 1615–1628 (2020).
- 727 19. Sawada, Y. *et al.* Cutaneous innate immune tolerance is mediated by epigenetic control of
728 MAP2K3 by HDAC8/9. *Sci. Immunol.* **6**, eabe1935 (2021).
- 729 20. Zhang, S. *et al.* Nonpeptidergic neurons suppress mast cells via glutamate to maintain skin
730 homeostasis. *Cell* **184**, 2151-2166.e16 (2021).
- 731 21. Mittermann, I. *et al.* IgE Sensitization Profiles Differ between Adult Patients with Severe
732 and Moderate Atopic Dermatitis. *PLoS One* **11**, e0156077 (2016).
- 733 22. Williams, H. C., Burney, P. G., Pembroke, A. C. & Hay, R. J. The U.K. Working Party's
734 Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. *Br J Dermatol*
735 **131**, 406–416 (1994).

- 736 23. Benhamou, P. H., Kalach, N., Soulaines, P., Donne, N. & Dupont, C. Ready-to-use house
737 dust mites atopy patch test (HDM-Diallertest), a new screening tool for detection of house
738 dust mites allergy in children. *Eur Ann Allergy Clin Immunol* **41**, 146–151 (2009).
- 739 24. Honda, T., Egawa, G. & Kabashima, K. Antigen presentation and adaptive immune
740 responses in skin. *Int Immunol* **31**, 423–429 (2019).
- 741 25. Ono, S. & Kabashima, K. [The role of dendritic cells and macrophages in the skin
742 immunity]. *Nihon Rinsho Meneki Gakkai Kaishi* **39**, 448–454 (2016).
- 743 26. Sirvent, S. *et al.* Genomic programming of IRF4-expressing human Langerhans cells. *Nat*
744 *Commun* **11**, 313 (2020).
- 745 27. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network
746 analysis. *BMC Bioinformatics* **9**, 559 (2008).
- 747 28. Vallejo, A. F. *et al.* Resolving cellular systems by ultra-sensitive and economical single-cell
748 transcriptome filtering. *iScience* **24**, 102147 (2021).
- 749 29. Reynolds, G. *et al.* Developmental cell programs are co-opted in inflammatory skin disease.
750 *Science* **371**, (2021).
- 751 30. Kiner, E. *et al.* Gut CD4(+) T cell phenotypes are a continuum molded by microbes, not by
752 T(H) archetypes. *Nat Immunol* **22**, 216–228 (2021).
- 753 31. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data
754 analysis. *Genome Biol* **19**, 15 (2018).
- 755 32. Lai, J.-J., Cruz, F. M. & Rock, K. L. Immune Sensing of Cell Death through Recognition of
756 Histone Sequences by C-Type Lectin-Receptor-2d Causes Inflammation and Tissue Injury.
757 *Immunity* **52**, 123-135.e6 (2020).

- 758 33. Mossotto, E. *et al.* GenePy - a score for estimating gene pathogenicity in individuals using
759 next-generation sequencing data. *BMC Bioinformatics* **20**, 254 (2019).
- 760 34. Karin, M. *et al.* Human metallothionein genes are clustered on chromosome 16. *Proc Natl*
761 *Acad Sci U S A* **81**, 5494–5498 (1984).
- 762 35. Hanifin, J. M. & Reed, M. L. A population-based survey of eczema prevalence in the United
763 States. *Dermatitis* **18**, 82–91 (2007).
- 764 36. Mortz, C. G., Bindslev-Jensen, C. & Andersen, K. E. Nickel allergy from adolescence to
765 adulthood in the TOACS cohort. *Contact Dermatitis* **68**, 348–356 (2013).
- 766 37. Yeung, H. *et al.* Psoriasis severity and the prevalence of major medical comorbidity: a
767 population-based study. *JAMA Dermatol* **149**, 1173–1179 (2013).
- 768 38. Seneschal, J., Clark, R. A., Gehad, A., Baecher-Allan, C. M. & Kupper, T. S. Human
769 epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident
770 regulatory T cells. *Immunity* **36**, 873–884 (2012).
- 771 39. Ballesteros-Tato, A. *et al.* T Follicular Helper Cell Plasticity Shapes Pathogenic T Helper 2
772 Cell-Mediated Immunity to Inhaled House Dust Mite. *Immunity* **44**, 259–273 (2016).
- 773 40. de Vries, I. J. *et al.* Adhesion molecule expression on skin endothelia in atopic dermatitis:
774 effects of TNF-alpha and IL-4. *J Allergy Clin Immunol* **102**, 461–468 (1998).
- 775 41. Danso, M. O. *et al.* TNF- α and Th2 cytokines induce atopic dermatitis-like features on
776 epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. *J*
777 *Invest Dermatol* **134**, 1941–1950 (2014).
- 778 42. Dunne, M. R. *et al.* Enrichment of Inflammatory IL-17 and TNF- α Secreting CD4(+) T Cells
779 within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and
780 Increased Expression of the Immune Checkpoint Molecule, PD-1. *Front Oncol* **6**, 50 (2016).

- 781 43. Polak, M. E. *et al.* CD70-CD27 interaction augments CD8+ T-cell activation by human
782 epidermal Langerhans cells. *J Invest Dermatol* **132**, 1636–1644 (2012).
- 783 44. Polak, M. E. *et al.* Distinct molecular signature of human skin Langerhans cells denotes
784 critical differences in cutaneous dendritic cell immune regulation. *J Invest Dermatol* **134**,
785 695–703 (2014).
- 786 45. Berthier-Vergnes, O. *et al.* TNF-alpha enhances phenotypic and functional maturation of
787 human epidermal Langerhans cells and induces IL-12 p40 and IP-10/CXCL-10 production.
788 *FEBS Lett* **579**, 3660–3668 (2005).
- 789 46. Kimber, I. & Cumberbatch, M. Stimulation of Langerhans cell migration by tumor necrosis
790 factor alpha (TNF-alpha). *J Invest Dermatol* **99**, 48S-50S (1992).
- 791 47. Davies, J. *et al.* Single cell transcriptomic analysis identifies Langerhans cells
792 immunocompetency is critical for IDO1- dependent ability to induce tolerogenic T cells.
793 *bioRxiv* 2019.12.20.884130 (2019) doi:10.1101/2019.12.20.884130.
- 794 48. Shklovskaya, E. *et al.* Langerhans cells are precommitted to immune tolerance induction.
795 *Proceedings of the National Academy of Sciences* **108**, 18049–18054 (2011).
- 796 49. Macal, M. *et al.* Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted
797 Plasmacytoid Dendritic Cells during Chronic Viral Infection. *Immunity* **48**, 730-744.e5
798 (2018).
- 799 50. Zent, C. S. & Elliott, M. R. Maxed out macs: physiologic cell clearance as a function of
800 macrophage phagocytic capacity. *FEBS J* **284**, 1021–1039 (2017).
- 801 51. Chan, T. K., Tan, W. S. D., Peh, H. Y. & Wong, W. S. F. Aeroallergens Induce Reactive
802 Oxygen Species Production and DNA Damage and Dampen Antioxidant Responses in
803 Bronchial Epithelial Cells. *J Immunol* **199**, 39–47 (2017).

- 804 52. Chan, T. K. *et al.* House dust mite-induced asthma causes oxidative damage and DNA
805 double-strand breaks in the lungs. *J Allergy Clin Immunol* **138**, 84-96.e1 (2016).
- 806 53. Kirino, M. *et al.* Heme oxygenase 1 attenuates the development of atopic dermatitis-like
807 lesions in mice: implications for human disease. *J Allergy Clin Immunol* **122**, 290–297,
808 297.e1–8 (2008).
- 809 54. Tsukahara, H. *et al.* Oxidative stress and altered antioxidant defenses in children with acute
810 exacerbation of atopic dermatitis. *Life Sci* **72**, 2509–2516 (2003).
- 811 55. Chopra, R. *et al.* Severity strata for Eczema Area and Severity Index (EASI), modified EASI,
812 Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity
813 Index and body surface area in adolescents and adults with atopic dermatitis. *Br J Dermatol*
814 **177**, 1316–1321 (2017).
- 815 56. Asher, M. & Weiland, S. The International Study of Asthma and Allergies in Childhood
816 (ISAAC). ISAAC Steering Committee. *Clinical and experimental allergy : journal of the*
817 *British Society for Allergy and Clinical Immunology* **28 Suppl 5**, 52—66; discussion 90—1
818 (1998).
- 819 57. Sandilands, A. *et al.* Comprehensive analysis of the gene encoding filaggrin uncovers
820 prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet* **39**, 650–
821 654 (2007).
- 822 58. Enomoto, H. *et al.* Filaggrin null mutations are associated with atopic dermatitis and elevated
823 levels of IgE in the Japanese population: a family and case-control study. *J Hum Genet* **53**,
824 615 (2008).
- 825 59. Pickard, C. *et al.* Investigation of mechanisms underlying the T-cell response to the hapten
826 2,4-dinitrochlorobenzene. *J Invest Dermatol* **127**, 630–637 (2007).

- 827 60. Macosko, E. Z. *et al.* Highly Parallel Genome-wide Expression Profiling of Individual Cells
828 Using Nanoliter Droplets. *Cell* **161**, 1202–1214 (2015).
- 829 61. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq
830 quantification. *Nat Biotechnol* **34**, 525–527 (2016).
- 831 62. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
832 differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140
833 (2010).
- 834 63. Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential analysis of RNA-
835 seq incorporating quantification uncertainty. *Nat Methods* **14**, 687–690 (2017).
- 836 64. Theocharidis, A., van Dongen, S., Enright, A. J. & Freeman, T. C. Network visualization and
837 analysis of gene expression data using BioLayout Express(3D). *Nat Protoc* **4**, 1535–1550
838 (2009).
- 839 65. Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list
840 enrichment analysis and candidate gene prioritization. *Nucleic Acids Res* **37**, W305–311
841 (2009).
- 842 66. Fleming, S. J., Marioni, J. C. & Babadi, M. CellBender remove-background: a deep
843 generative model for unsupervised removal of background noise from scRNA-seq datasets.
844 *bioRxiv* (2019) doi:10.1101/791699.
- 845 67. Bernstein, N. J. *et al.* Solo: Doublet Identification in Single-Cell RNA-Seq via Semi-
846 Supervised Deep Learning. *Cell Syst* **11**, 95–101.e5 (2020).
- 847 68. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-
848 connected communities. *Scientific Reports* **9**, 5233 (2019).

- 849 69. Finak, G. *et al.* MAST: a flexible statistical framework for assessing transcriptional changes
850 and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biol* **16**, 278
851 (2015).
- 852 70. Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server
853 2016 update. *Nucleic Acids Res* **44**, W90-97 (2016).
- 854 71. Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J. P. GSEA-P: a desktop
855 application for Gene Set Enrichment Analysis. *Bioinformatics* **23**, 3251–3253 (2007).
- 856 72. Garcia-Alonso, L. *et al.* Transcription Factor Activities Enhance Markers of Drug Sensitivity
857 in Cancer. *Cancer Res* **78**, 769–780 (2018).
- 858 73. Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB:
859 inferring cell-cell communication from combined expression of multi-subunit ligand-
860 receptor complexes. *Nat Protoc* **15**, 1484–1506 (2020).
- 861 74. Nagai, J. S., Leimkühler, N. B., Schaub, M. T., Schneider, R. K. & Costa, I. G. CrossTalker:
862 Analysis and Visualisation of Ligand Receptor Networks. *Bioinformatics* (2021)
863 doi:10.1093/bioinformatics/btab370.
- 864 75. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–
865 2079 (2009).
- 866 76. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing
867 next-generation DNA sequencing data. *Genome Res* **20**, 1297–1303 (2010).
- 868 77. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biology* **17**, 122 (2016).
- 869 78. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic
870 features. *Bioinformatics* **26**, 841–842 (2010).

871

872 **Acknowledgments:**

873 We acknowledge the use of the IRIDIS High Performance Computing Facility and Flow
874 Cytometry Core Facilities, together with support services at the University of
875 Southampton. Authors wish to acknowledge Nikki Graham, Senior Technician within the
876 DNA laboratory, Dr Carolann McGuire and Dr Richard Jewell from Flow Cytometry Core
877 for technical support. We are grateful to nurses and administrative staff at the Clinical
878 Research Facility, NIHR, University Hospital Southampton NHS Foundation Trust. We
879 express our deepest gratitude to the patients recruited to the study.

880 **Funding:**

881 This research was funded in whole by the Wellcome Trust [Sir Henry Dale Fellowship
882 109377/Z/15/Z]. For the purpose of open access, the author has applied a CC BY public
883 copyright licence to any Author Accepted Manuscript version arising from this
884 submission.

885

886 **Author contributions:**

887 MEP, MAJ and HS: intellectually conceived the study,
888 EC, YT, SH, GR, NH, MAJ, RA, MEP: patient recruitment and clinical data acquisition
889 SS, AV, LD, ML, NG, RA, CL: carried out experiments
890 SS, AV, MEP, KC: carried out analysis and meta-analysis of bulk RNA-seq data
891 SS, AV, MEP, KC, JD: carried out analysis and meta-analysis of single cell RNA-seq
892 data
893 ES and SE: carried out WES data analysis
894 SS, AV, MEP: wrote the manuscript
895 MAJ, PF, HS, EH, CLB: discussed, and reviewed the manuscript

896 **Competing interests:**

897 The Authors declare no conflict of interest

898 **Data and materials availability:**

899 Sequencing data for RNA-seq and scRNA-seq is stored in Gene Expression Omnibus
900 database. The exome sequencing data underlying this article cannot be shared publicly
901 due to ethical considerations.

902

903 **Supplementary Materials**

904

905 **Supplementary Materials and Methods: Experimental Procedures**

906

907 **Supplementary Figures**

908 Supplementary Figure 1. *In vivo* allergen challenge model to investigate mechanisms of
909 local immune responses in human skin.
910 Supplementary Figure 2 Reactivity to HDM is mediated by co-expansion of T cells and
911 LCs.
912 Supplementary Figure 3 HDM reactivity in reactive patients is mediated by LC : T cell
913 TNF crosstalk and impairs LC transcriptional programming
914 Supplementary Figure 4 Activated TNF-expressing Th17 cells are significantly enriched
915 at baseline in reactive patients

916 Supplementary Figure 5 Sub-clinical inflammation and environmental stress in
917 differentiated keratinocytes poise immune status of reactive patients

918 Supplementary Figure 6 Enhanced expression of metallothionein genes protects non-
919 reactive patients from HDM-induced T cell-mediated inflammation

920

921 **Supplementary Tables: attached as csv files**

Supplementary Table 1	Patient characteristics
Supplementary Table 2	FLG mutations
Supplementary Table 3	KC signatures
Supplementary Table 4	LC transcriptional programme at baseline
Supplementary Table 5	BioLayout modules and Gene Ontology analysis
Supplementary Table 6	WGCNA modules and Gene Ontology analysis
Supplementary Table 7	Panel of genes for Constellation-seq
Supplementary Table 8	Cluster defining marker genes
Supplementary Table 9	DEGs in KC Constellation-seq
Supplementary Table 10	DEGs in all cells : contrast in HDM exposed samples
Supplementary Table 11	Gene signatures for GWAS
Supplementary Table 12	WGCNA module Turquoise: Top 100 genes

922

923

924

925

926 **Supplementary Materials and Methods: Experimental Procedures**

927

928 **Study Design:**

929 Objective EASI was measured as described previously⁵⁵. Before sampling, patients were
930 washed out from any immunosuppressive treatment for at least 5 half-lives of the drug.
931 Atopy status was assessed for each patient using Skin Prick Test (SPT) to six most
932 common allergens: house dust mite, grass pollen, tree pollen mix, mixed mould, cat and
933 dog plus histamine as a positive control (ALK-Abello, Horsholm, Denmark). Maintenance
934 of normal epidermal barrier function was measured by trans-epidermal water loss
935 (TEWL). On enrolment, information about participants' demographics and previous
936 medical history, immediate family history and information about atopic disease (eg
937 eczema, rhinitis) in the subject was collected based on the ISAAC questionnaire⁵⁶.
938 Peripheral blood mononuclear cells (PBMC) were separated from venous blood and
939 processed for DNA extraction. FLG mutation analysis was performed as described
940 previously^{57,58}. Briefly, primer pairs were used to amplify the region of interest from DNA
941 prepared from peripheral blood samples of individuals with atopic dermatitis and controls.
942 FLG variants R501X, 2282del4, S3247X and R2447X, which covers more than 90% of
943 FLG mutations in a UK population, were then identified using restriction enzyme digest of
944 PCR products with agarose gel electrophoresis and FLG variants were confirmed by
945 whole exome sequencing.

946

947 **Cell isolation**

948 6 mm biopsies were minced using a surgical scalpel and digested for 16h at 37C with
949 agitation in RPMI with LiberaseTM (Roche) following manufacturer's instructions. After
950 16h of digestion cells were collected and washed with RPMI 5% FBS. Cells were
951 resuspended in PBS 1% BSA 20mM EDTA and filtered through 70um sterile filters before
952 surface antibody staining for FACS or processing for Dropseq analysis.

953

954 **Flow cytometry and cell sorting**

955 All antibodies were used at pre-titrated, optimal concentrations. For surface staining of
956 live cells buffer containing PBS 1% BSA was used for all antibody staining. FACS Aria
957 flow cytometer (Becton Dickinson, USA) was used for analysis of human LCs for the
958 expression of CD207, CD1a, HLA-DR (mouse monoclonal antibodies, CD1a,
959 CD207:Miltenyi Biotech, UK and HLA-DR: BD Biosciences, UK) or T cells for the
960 expression of CD3, CD25 and CD103 (Miltenyi Biotech). Freshly isolated PBMCs were
961 activated with anti-CD3 and anti-CD28 (1 mg/ μ l), with GolgiPlug (BD Biosciences,
962 Oxford, UK). The Cytotfix/Cytoperm kit (BD Biosciences) was used according to the
963 manufacturers' instructions.

964 Flow cytometric analysis with the FACS Aria flow cytometer (BD Biosciences) was
965 undertaken following lymphocyte gating on Forward/Side scatter. Subsequent gating on
966 CD3- PerCP 5.5 (eBiosciences), CD4-VioGreen (Miltenyi Biotech) was based on
967 appropriate negative controls to demonstrate IL13-APC and IL-17-FITC positive cells
968 (Miltenyi Biotech) for analysis with the FlowJo software (Tree Star, Ashland).

969 Singlets (FCSA:FCSH), CD207+/CD1a+ digested LCs were sorted into trizol for RNA
970 isolation. In parallel, LC-depleted skin cells were sorted into RPMI 5% FBS and processed
971 for immediate cryostorage.

972

973 **Immunofluorescence microscopy of frozen tissue sections**

974 Snap frozen skin samples were embedded in OCT (CellPath) and cut to 5-10 μm
975 cryosections onto APES-coated slides. Sections were fixed in 4% paraformaldehyde,
976 washed with PBS, blocked with PBS + 1% BSA + 10% FBS and incubated for 30 minutes
977 with primary antibodies to the following markers: Langerin (Leica), multi-cytokeratin
978 (Leica), CD3 (Dako), CD4 (Abcam), CD8 (Abcam) or FOXP3 (Abcam). After washing off
979 the primary antibodies, secondary antibodies were added; these included: Alexa Fluor
980 488 goat anti-mouse IgG1a, Alexa Fluor 555 goat anti-rabbit IgG, and Alexa Fluor 647
981 goat anti-mouse IgG2b (all from ThermoFisher Scientific). Sections were then
982 counterstained with DAPI (Sigma), mounted with Mowiol (Harco), coverslipped and
983 imaged using an Olympus Dotslide scanning fluorescence microscope and Olympus VS-
984 Desktop software.

985

986 **RNA-seq**

987 RNA was isolated using Direct-zol RNA micro prep (Zymo, UK) as per the manufacturer's
988 protocol. RNA concentration and integrity was determined with an Agilent Bioanalyser
989 (Agilent Technologies, Santa Clara, CA. Preparation of RNA-seq libraries and sequencing
990 were carried out by Source Bioscience, UK. cDNA libraries were generated using
991 SMART-Seq Stranded Library Preparation for Ultra Low Input according to the SMART-
992 Seq Stranded Kit User Manual following the Ultra low input workflow (Takara Bio).
993 Samples were pooled (12/batch) for library preparation. Amplified libraries were validated
994 on the Agilent BioAnalyzer 2100 to check the size distribution and on the Qubit High
995 Sensitivity to check the concentration of the libraries. All the libraries passed the QC step.
996 Sequencing was done on Illumina HiSeq 4000 instrument, 75bp PE runs, 20×10^6 reads
997 per sample.

998

999 **Drop-seq**

1000 Freshly dissociated whole skin biopsies were suspended in RNase-out buffer and
1001 processed on ice to the co-encapsulation of single cells with genetically-encoded beads
1002 (Drop-seq, ⁶⁰). Monodisperse droplets at 1 nl in size were generated using the microfluidic
1003 devices fabricated in the Centre for Hybrid Biodevices, University of Southampton. To
1004 achieve single cell/single bead encapsulation with barcoded Bead SeqB (Chemgenes,
1005 USA), microfluidics parameters (pump flow speeds for cells and bead inlets, cell
1006 buoyancy) were adjusted to optimise cell-bead encapsulation and the generation of high
1007 quality cDNA libraries. Based on encapsulation frequencies and bead counts up to 2000
1008 STAMPS /sample were taken further for library prep (High Sensitivity DNA Assay, Agilent
1009 Bioanalyser, 12 peaks with the average fragment size 500 bp). The resulting libraries
1010 were run on a shared NextSeq run (4×10^4 reads/cell for maximal coverage) at the Wessex
1011 Investigational Sciences Hub laboratory, University of Southampton, to obtain single cell
1012 sequencing data

1013

1014 **Constellation-seq**

1015 Single cell libraries were generated using the Chromium Single Cell 3' library and gel
1016 bead kit v3.1 from 10x Genomics. Briefly, cell suspensions were tagged using TotalSeq™
1017 hashtag antibodies (Biolegend). After pooling, 10,000 viable cells were loaded onto a

1018 channel of the 10x chip to produce Gel Bead-in-Emulsions (GEMs). This underwent
1019 reverse transcription to barcode RNA before clean-up and cDNA amplification. cDNA was
1020 used for targeted linear amplification comprising 20 rounds of linear amplification (60°C)
1021 using a pool of primers (Supplementary Table 7) at 40 nM and 0.4 µM of a P5 3'blocked
1022 primer as described previously(Vallejo et al). cDNA libraries were purified twice using
1023 AMPure XP (Beckman Coulter) magnetic beads (1:0.6) and libraries assessed using a
1024 Bioanalyser before tagmentation and Next-seq sequencing on an Illumina Nextseq500,
1025 (paired end 28x60 bp reads).

1026

1027 **Bulk RNA-seq data analysis**

1028 Quality control for FASTQ files with raw sequence data was done using FASTQC tool
1029 [FastQC: a quality control tool for high throughput sequence data. Available online at:
1030 <http://www.bioinformatics.babraham.ac.uk/projects/fastqc>]. High-quality reads filtered at
1031 15M depth across all samples were mapped to the human genome (GRCh38) using
1032 Kallisto⁶¹. Raw counts from RNA-Seq were processed in Bioconductor package EdgeR
1033 ⁶² and SLEUTH⁶³, variance was estimated and size factor normalized using trimmed
1034 mean of M-values (TMM). Genes with minimum 2 reads at minimum 50% samples were
1035 included in the downstream analyses. Differentially expressed genes (DEG) we identified
1036 applying significance threshold FDR $p < 0.05$, $|\text{LogFC}| > 1$. Normalised reads were taken
1037 for transcript-to-transcript co-expression analysis (BioLayout ⁶⁴). Pearson correlation
1038 coefficient $r = 0.85$, Markov Clustering Algorithm = 1.7.. WGCNA analysis ²⁷ were run on
1039 5000 genes with maximum median absolute deviation (MAD), at power=4 module size
1040 30 in R v 4.0.3 using voom transformed (TMM) normalised expression data. Gene
1041 ontology analysis across clusters and modules was done using ToppGene online tool⁶⁵.

1042

1043 **scRNA-seq data and Constellation-seq analysis** Single cell RNA-seq and
1044 Constellation-seq analysis was carried out using pipelines established in Systems
1045 Immunology Group ^{26,28}. Following demultiplexing, raw FASTQ files were aligned to the
1046 human genome (GRCh38), using kallisto-bustools ⁶¹. CellBender⁶⁶ was used to remove
1047 empty technical artefacts. Doublet detection and hashing demultiplexing was done using
1048 Solo ⁶⁷. Visualization and clustering of scRNAseq was performed in Scanpy ³¹ following
1049 standard quality checks (empty barcodes, percentage of mitochondrial genes). Clusters
1050 were determined via single-cell neighbourhood analyses on first principal components
1051 followed by clustering and cell type identification (leiden-based clustering ⁶⁸. Cell types
1052 were annotated based on the expression of known marker genes, and cross-validated
1053 using publically available single cell transcriptomes ²⁹. Differentially regulated
1054 transcriptional networks were identified using model-based analysis of single-cell
1055 transcriptomics MAST ⁶⁹. Specific transcriptional signatures were tracked using Gene Set
1056 Expression Analysis ^{70,71}. Transcription factor activity prediction was done using
1057 DoRothEA⁷². Cell-cell communication was inferred using CephoneDB⁷³ and CosstalkR
1058 ⁷⁴.

1059

1060 **Whole Exome Data generation**

1061 Whole exome sequencing was performed by Macrogen, with data uploaded to the
1062 University of Southampton supercomputer IRIDIS5 in February 2021. Agilent SureSelect
1063 Human All Exon V6 capture kit was used for all 28 samples.

1064

1065 **Whole exome data analysis**

1066 The raw fastq files were aligned to the human genome reference GRCh38 with additional
1067 HLA regions included. Alignment was performed using BWA-MEM v0.7.15-r1140 and
1068 Samtools⁷⁵ v1.3.1. Picard (<http://broadinstitute.github.io/picard/>) was used to mark
1069 duplicates, sort the BAM files, index, and fix the mate pairs. GATK⁷⁶ v4 base quality score
1070 recalibration (BQSR) was used to detect systematic errors by the sequencing machine
1071 when it estimates the accuracy of each base call. Joint-calling was executed using a
1072 bespoke script. GATK GenomicsDBImport was used to create a database of all g.vcf files
1073 for joint-calling and was targeted to the intersection between Agilent SureSelect V6 and
1074 Agilent SureSelect V5, both with +/-150bp padding. GATK Genotype GVCF was applied
1075 to joint-call the 28 AD samples with 1100 inflammatory bowel disease patients. A final
1076 script applied GATK Variant Quality Score Recalibration (VQSR), a technique applied on
1077 the variant callset that uses machine learning to model the technical profile of variants in
1078 a training set and uses that to flag probable artefacts from the callset. Annotation was
1079 completed using Ensembl VEP⁷⁷ v103. The joint-called vcf was uploaded to a local
1080 installation of seqr (<https://github.com/broadinstitute/seqr>) on a virtual machine for data
1081 visualisation, analysis, filtering and reporting. A suite of bespoke scripts was used to
1082 assess quality control. Bedtools⁷⁸ v2.26.0 was applied to calculate exome data coverage
1083 relative to the target capture kit. GATK VariantEval tool was used to calculate various
1084 quality control metrics including: the number of raw or filtered SNPs and the ratio of
1085 transitions to transversions. These metrics are further stratified by functional class, CpG
1086 site, and amino acid degeneracy. Picard CollectVariantCallingMetrics was applied to
1087 collect the per-sample and aggregate (spanning all samples) metrics from the provided
1088 vcf file. Peddy (<https://github.com/brentp/peddy>) was executed locally in a python conda
1089 environment to assess the relatedness of individuals, and predict their ancestry and sex.
1090 All QC metrics data were compiled into a Shiny App using R v4.2.0 for data visualisation.

1091

1092 **Identifying filaggrin variants:**

1093 We selected all loss of function filaggrin (FLG) variants with a maximum allele frequency
1094 (across all populations in gnomAD) of <0.05, allele balance of >0.2 and genotype quality
1095 > 0.3 with variants in FLG , with VQSR applied as a flag.

1096

1097 **Applying GenePy to identify genes enriched in reactive vs non-reactive patients:**

1098 We assessed the difference in gene mutation burden between patients non-reactive and
1099 reactive to HDM using GenePy 1.3 (Mossotto et al). We initially calculated GenePy scores
1100 for a pre-selected 34 genes (Supplementary Table 11) and compared their scores
1101 between non-reactive and reactive patients using logistic regression. We extrapolated
1102 this analysis to 2002 autoimmune genes (Supplementary Table 11) and compared
1103 GenePy scores using a Mann-Whitney-U test.

1104

1105 **Statistical analysis:** All statistical analysis were carried out using GraphPad Prism
1106 V9.2.0 unless specifically state otherwise.

1107

1108 **Data Availability:** Sequencing data for RNA-seq and scRNA-seq is stored in Gene
1109 Expression Omnibus database. The exome sequencing data underlying this article
1110 cannot be shared publicly due to ethical considerations.


1111

1112 **Supplementary Figures**

1113

1114 **Supplementary Figure 1.**

1115



1116


1117

1118 **Supplementary Figure 1. *In vivo* allergen challenge model to investigate mechanisms of local**

1119 **immune responses in human skin.**
1120 Patient cohort characteristics: A) age, gender, ethnicity, EASI score, n=28. B) trans-epidermal water
1121 loss (TEWL) in patients with AD and healthy controls, C) Skin Prick Test (SPT) responses to stimulation
1122 with 6 most common allergens (wheat area given). D) Recorded responses to ISAAC questionnaire, 1
1123 represents 100% of positive responses to questions in a category.

1124


1125 **Supplementary Figure 2**



1126
 1127 **Supplementary Figure 2 Reactivity to HDM is mediated by co-expansion of T cells and LCs.**
 1128 A) Number of irritant (IRR), non-reactive (NON), and reactive (REAC) cases with loss of function (LoF)
 1129 variants in FLG compared to wildtype (WT). 7 SNP measured using Whole Genome Sequencing, n=27

1130 patients. B) Z scores for keratinocyte gene expression programmes, DropSeq whole transcriptome
1131 analysis, fresh tissue, n=6 paired biopsies from 3 donors CR: control reactive, HR: HDM reactive, CNR:
1132 control non-reactive, HNR: HDM non-reactive C) Fold changes in percentage of detected DDC between
1133 HDM patch test and control patch test from patients with irritant, non-reactive and reactive reactions to
1134 HDM. Statistical significance assessed by t-test D) Correlations between fold changes in percentage of
1135 CD3+ T cells and DDCs. Pearson correlation coefficient shown. N) Immunofluorescence staining of patch
1136 test sites from reactive and non-reactive patients. Inserts show the indicated optical fields. CD207 (green)
1137 and CD3 (red). Epidermal layer stained with multi-cytokeratin (blue). DAPI stain for nuclei (grey). In patch
1138 test from HDM exposed non-reactive patient example of interaction between CD4 (red) and CD8 (cyan) T
1139 cells shown.
1140


1141 **Supplementary Figure 3**



1142 **Supplementary Figure 3 HDM reactivity in reactive patients is mediated by LC : T cell TNF**
 1143 **crossstalk and impairs LC transcriptional programming**
 1144 A) Gating strategy for sorting CD207+CD1a+ Langerhans cells, B) Transcript-to-transcript correlation
 1145 network of 10 largest clusters detected in LC transcriptomes. Lines (edges) represent the similarity between
 1146

1147 transcripts, circles (nodes) represent genes. C) Mean (\pm SEM) expression profiles for clusters 1-10, across
1148 sample groups. CI: control irritant, HI: HDM irritant, CR: control reactive, HR: HDM reactive, CNR: control
1149 non-reactive, HNR: HDM non-reactive. Dots represent average expression of transcript. Statistical
1150 comparison done using Mann Whitney test for paired samples. D) WGCNA analysis of correlation between
1151 clinical and experimental features, recorded as continuous variables and eigenvectors representing
1152 modules of co-expressed genes across LC transcriptomes. Each colour coded module (left) represents co-
1153 expressed genes. Clinical/experimental features are labelled across X axis. Person correlation coefficients
1154 and p-values are given for each correlation, the heatmap (blue to red) indicates correlation strength and
1155 direction.
1156


1157 **Supplementary Figure 4**
1158



1159 **Supplementary Figure 4 Activated TNF-expressing Th17 cells are significantly enriched at baseline**
1160 **in reactive patients**
1161
1162 A) Composition of T cell subsets (HCA profiles) across patch test phenotypes. CR: control reactive, HR:
1163 HDM reactive, CNR: control non-reactive, HNR: HDM non-reactive. B) Th immunotypes gene signature
1164 across patient groups, dotplot: size depict % of expressing cells, colour intensity encodes mean expression

1165 in group C) %IL13 producing CD3+CD4+ Tcells from PBMCS in non-reactive (NRC) and reactive (R)
1166 patients. T-test. C) UMAP plot of 2374 single T lymphocytes cells. Constellation-seq analysis enriched for
1167 1161 transcripts from patch test skin biopsies, n=10 patients, 5 per group. Th immunotypes for T cell
1168 polarisation shown (Z-score, green to red). D) Gating strategy for flow cytometry analysis of intracellular
1169 cytokine staining.
1170


1171 **Supplementary Figure 5**
1172




1173 **Supplementary Figure 5 Sub-clinical inflammation and environmental stress in differentiated**
1174 **keratinocytes poise immune status of reactive patients**
1175

1176 A-C) Quality controls for constellation-seq analysis enriched for 1161 transcripts in 25844 single cells from
1177 patch test skin biopsies, n=10 patients A) BBKNN integration across treatment and condition B) BBKNN
1178 integration across donors C) percentage of mitochondrial genes across samples UMAP plot depicting
1179 clustering of specific cell populations B) Cell subset defining markers (Wilcoxon rank test) D-E) DropSeq
1180 analysis of whole transcriptome across single cells isolated from fresh whole skin biopsies. N=6 paired
1181 samples, 3 donors. D) UMAP plot depicting clustering of specific cell populations E) Violin plots showing Z
1182 score of KC inflammation signature across skin layers, CR: control reactive, HR: HDM reactive, CNR:


1183 control non-reactive, HNR: HDM non-reactive F) Gene Ontology enrichment in DEGs identified across cell
 1184 populations in Constellation seq.
 1185 **Supplementary Figure 6**
 1186
 1187



B



C



1188 **Supplementary Figure 6 Enhanced expression of metallothionein genes protects non-reactive**
 1189 **patients from HDM-induced T cell-mediated inflammation**
 1190

1191 A) Constellation-seq analysis, DEGs overexpressed in non-reactive vs reactive patients B) Schematic
 1192 depicting localisation of SNP in promoter/enhancer region upstream of MT1X, significantly enriched in
 1193 patients tolerant to HDM C) Processes significantly enriched in module turquoise, correlating with CD3

1194 infiltrate in skin. Top processed up-regulated (blue) and downregulated (orange) with CD3 infiltration shown.
1195 Red line denotes significance cut-off by FDR p value.